You are here: Industry Insights > Nanoform

News List

Nanoform Signs GMP Manufacturing Program with TargTex contractpharma
February 04, 2022
Aims to enhance TargTex’s Glioblastoma multiforme drug candidate.
Nanoform convenes EGM to elect Jeanne Thoma as board member prnasia
October 18, 2021
Nanoform Finland Plc ("Nanoform"), an innovative nanoparticle medicine enabling company, will convene an extraordinary general meeting (EGM) on November 17, 2021, at 14:00 EEST to elect Jeanne Thoma as a new board member.
Nanoform and Boehringer Ingelheim execute master services agreement prnasia
August 03, 2021
Nanoform, an innovative nanoparticle medicine enabling company, announces that Proof of Concept studies may now be performed for Boehringer Ingelheim to assess the added value Nanoform's award-winning CESS® technology can deliver to its drug development p
Nanoform and Celanese Explore Ways to Enhance Drug Delivery prnasia
May 26, 2021
Nanoform Finland Plc announced plans to explore the synergies between their respective technologies in the field of nanoparticle-enabled drug delivery.
Nanoform's final clinical results confirm value proposition to the pharma industry prnasia
May 18, 2021
Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, today announced the completion and final results of its clinical study. The primary, secondary and optional exploratory objectives of the study were all met.
Nanoform, Aprecia Partner to Advance 3DP Nanomedicines contractpharma
April 23, 2021
Nanoform Finland Plc, a nanoparticle medicine enabling company, and Aprecia, the 3DP (three-dimensional printing) pharmaceutical company, have partnered to explore synergies between their respective technologies in the field of nanoparticle-enabled ...
Additional Positive Interim Results from Nanoform's Clinical Study prnasia
February 24, 2021
Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, today announced further positive interim results from its ongoing clinical study.
Nanoform's Clinical Study Indicates Positive Interim Results prnasia
January 22, 2021
Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, today announced positive interim results from its clinical study. The faster absorption data implies that small particles can indeed be powerful.
Nanoform initiates GMP campaign for first-in-human trial of nanoformed drug by year end - ahead of schedule prnasia
October 22, 2020
Nanoform Finland Plc, an innovative nanoparticle medicine enabling company will, in the fourth quarter of 2020, start the first ever human trial of a drug candidate nanoformed using Nanoform's proprietary CESS® technology.
Nanoform Awarded GMP Certification contractpharma
May 07, 2020
To manufacture investigational drug developed using its CESS nanoparticle engineering platform for use in clinical trials.

Previous page 1 2 Next page